The 2026 news about tau scans, which map tangles tied to Alzheimer's, adds detail to workups but keeps first steps for new symptoms unchanged. Tauklarify is a tracer for that scan in impaired adults under Alzheimer's evaluation, so do not seek a scan first.
Lantheus reports FDA approval of Tauklarify (florquinitau F 18) on Aug. 14, 2026, for tau PET imaging in impaired adults evaluated for Alzheimer's in the Lantheus approval announcement. Lantheus describes tau PET as added detail with amyloid PET and other tools, not a standalone workup.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Who is the scan meant for?
- Why one scan cannot diagnose Alzheimer's alone?
- What limits affect the result?
- What should you do first for new symptoms?
Who is the scan meant for?
The approved use is narrow. It covers adults with cognitive impairment who are being evaluated for Alzheimer's disease to identify tau tangle pathology. It does not cover routine checks for people without memory or thinking problems.
Use this eligibility check before asking a clinic about tau PET. All points should fit for the approved use. Cleveland Clinic, summarizing International Working Group guidance, advises against routine biomarker testing without impairment in clinical care in the Cleveland Clinic diagnosis summary. That boundary keeps the new scan out of wellness screening.
- ongoing cognitive impairment, not occasional forgetfulness
- evaluation focused on Alzheimer's disease
- clinician-directed testing, not direct-access screening
Why one scan cannot diagnose Alzheimer's alone?
A clinical Alzheimer's diagnosis needs both a characteristic syndrome and positive amyloid-beta plus tau markers. Cleveland Clinic, summarizing International Working Group guidance, classifies unimpaired biomarker-positive people as at-risk rather than clinically diagnosed. The Alzheimer's Association's 2024 revised criteria keep that pairing through integrated biological-plus-clinical staging.
Core 1 markers include amyloid PET, approved spinal-fluid tests, and accurate blood tests such as p-tau217, while tau PET helps stage or refine. That structure places tau PET as follow-up detail, not solo screening. Think of amyloid PET as showing one required pathology and tau PET as adding location and extent for staging. Neither result alone replaces history, exam, and cognitive testing.
What limits affect the result?
Practical Neurology, reporting prescribing information, warns performance may drop in earlier disease stages in the Practical Neurology report on the approval. Labeling notes a negative scan does not exclude tau tangle pathology, and a positive scan does not prove confirmed pathology on tissue examination. Lantheus notes the label has not established safety and effectiveness for non-Alzheimer's tau diseases.
It therefore does not evaluate progressive supranuclear palsy, frontotemporal lobar degeneration, or other tau diseases. An early negative result still needs clinical follow-up when symptoms persist. A positive result still needs a clinician to fit it to symptoms, amyloid status, and other causes.
What should you do first for new symptoms?
Start with clinician-led history, cognitive testing, and routine labs, not a scan request. Lantheus says it will support therapeutic programs through Pharma Solutions while assessing broader commercial availability. Do not expect immediate direct access to tau PET after the approval headline.
Make the first visit productive with dated notes. Bring these items and ask these questions: Ask how amyloid and tau testing fit only after those basic steps. Ask what follow-up interval fits if symptoms persist after normal basic results.
- examples of lapses, dates, and daily impact
- full medication and health history
- whether cognitive testing and routine labs fit now
- when referral or biomarker testing would fit
You Might Also Like
- Tauklarify Imaging for Alzheimer’s Tau Tangles in 2026: How Adults With New Memory Symptoms Can Avoid Overreading the Headline
- Tauklarify Tau PET vs Alzheimer’s Blood Tests in 2026: How Adults With New Memory Symptoms Can Avoid Overreading the Headline
- The Third FDA-Cleared Alzheimer’s Blood Biomarker Test in 2026: How Adults With New Memory Symptoms Can Avoid Overreading the Headline
